데이터를 보충하는 중입니다. 잠시 후 페이지를 새로 고치면 최신 내용을 볼 수 있습니다
70280-03-4CC(=O)N[C@H]1[C@H](O[C@@H]([C@H](O[C@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(=O)O)C(N)=O)[C@H](C=O)NC(C)=O)[C@H](O)CO)O[C@H](CO)[C@@H](O)[C@@H]1OJPBBNLWRCVBGJS-KCAUTNRHSA-N70280-03-4DTXSID70990489CHEBI:135873안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.
개요N-acetyl-β-D-glucosaminyl-( 1→4)-N-acetylmuramyl-L-alanyl-D-isoglutamine was launched in Russia for hospital-related infections, psoriasis, cervical precancerous lesions and ophthalmic keratitis caused by herpes. It was found to be less pyrogenic than MDP, the minimally active component of Freund's complete adjuvant. While chemical synthesis is possible, a less laborious method (3 steps) involves the enzymatic degradation of a bacterial peptidoglycan. GDMP is orally active with a low toxicity that acts as an adjuvant to highly purified protein antigens to stimulate the induction of CD8* T-cell response. It was also able to reduce the levels of TNF-α, IL-1α and hypoglycemia induced by LPS administration and to inhibit systemic response to endotoxin.
현재 필터 조건에 해당하는 반응 기록이 없습니다.
불러오는 중…